| 1.24 -0.05 (-3.88%) | 01-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.76 | 1-year : | 2.18 |
| Resists | First : | 1.5 | Second : | 1.87 |
| Pivot price | 1.41 |
|||
| Supports | First : | 0.92 | Second : | 0.76 |
| MAs | MA(5) : | 1.33 |
MA(20) : | 1.4 |
| MA(100) : | 1.01  |
MA(250) : | 0.99 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26.7 |
D(3) : | 34 |
| RSI | RSI(14): 43.9 |
|||
| 52-week | High : | 3.05 | Low : | 0.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BSGM ] has closed above bottom band by 2.8%. Bollinger Bands are 39.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.32 - 1.33 | 1.33 - 1.34 |
| Low: | 1.19 - 1.2 | 1.2 - 1.21 |
| Close: | 1.23 - 1.24 | 1.24 - 1.25 |
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Wed, 08 Jan 2025
BioSig: A Useless Product, A Paid Stock Promotion, And Unrevealed Clinical Studies Data (NASDAQ:BSGM) - Seeking Alpha
Thu, 14 Nov 2024
BioSig Technologies Inc. (BSGM) Quarterly 10-Q Report - Quartz
Wed, 13 Nov 2024
BioSig Regains Compliance with Nasdaq’s Minimum Bid Price Requirement - GlobeNewswire
Wed, 13 Nov 2024
BioSig Technologies Regains Nasdaq Compliance, Secures Market Position with FDA-Cleared Platform - StockTitan
Tue, 22 Oct 2024
BioSig granted grace period to meet Nasdaq listing requirements - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | -4 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.723e+007 (%) |
| Held by Institutions | 1.156e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.35 |
| Profit Margin | 0 % |
| Operating Margin | -40 % |
| Return on Assets (ttm) | 707.6 % |
| Return on Equity (ttm) | -326.5 % |
| Qtrly Rev. Growth | 342 % |
| Gross Profit (p.s.) | 276.92 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.838e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -0.93 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 183440 |
| Forward Dividend | 514310 |
| Dividend Yield | 14793500% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|